UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Journal of clinical oncology, 2020-06, Vol.38 (18), p.2080-2106

2020

Volltextzugriff (PDF)

Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer

Clinical cancer research, 2016-01, Vol.22 (1), p.26-33

2016

Volltextzugriff (PDF)

Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test

Cancer, 2017-11, Vol.123 (22), p.4363-4371

2017

Volltextzugriff (PDF)

Patient preferences regarding incidental genomic findings discovered during tumor profiling

Cancer, 2016-05, Vol.122 (10), p.1588-1597

2016

Volltextzugriff (PDF)

Increased epigenetic age in normal breast tissue from luminal breast cancer patients

Clinical epigenetics, 2018-08, Vol.10 (1), p.112-11, Article 112

2018

Volltextzugriff (PDF)

PALB2 mutations in familial breast and pancreatic cancer

Familial cancer, 2011-06, Vol.10 (2), p.225-231

2011

Volltextzugriff (PDF)

Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability

Molecular cancer, 2008-12, Vol.7 (1), p.91-91, Article 91

2008

Volltextzugriff (PDF)

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update

Journal of clinical oncology, 2019-11, Vol.37 (33), p.JCO1901472-3165

2019

Volltextzugriff (PDF)

Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients

Mayo Clinic proceedings, 2021-04, Vol.96 (4), p.1033-1040

2021

Volltextzugriff (PDF)

Impact of financial burden of cancer on survivors' quality of life

Journal of oncology practice, 2014-09, Vol.10 (5), p.332

2014

Volltextzugriff (PDF)

A Case of Pheochromocytoma as a Subsequent Neoplasm in a Survivor of Childhood Embryonal Rhabdomyosarcoma

Journal of pediatric hematology/oncology, 2022-03, Vol.44 (2), p.e585

2022

Volltextzugriff (PDF)

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer

Breast cancer research and treatment, 2018-06, Vol.169 (2), p.333-340

2018

Volltextzugriff (PDF)

Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer

European journal of cancer prevention, 2016-01, Vol.25 (1), p.3

2016

Volltextzugriff (PDF)

Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice

Breast cancer research : BCR, 2011-03, Vol.13 (2), p.R30-R30, Article R30

2011

Volltextzugriff (PDF)

The Number of Lymph Nodes Dissected in Breast Cancer Patients Influences the Accuracy of Prognosis

Annals of surgical oncology, 2014-02, Vol.21 (2), p.389-394

2014

Volltextzugriff (PDF)

Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer

Clinical breast cancer, 2016-02, Vol.16 (1), p.59-62

2016

Volltextzugriff (PDF)

The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report

The Yale journal of biology & medicine, 2015-06, Vol.88 (2), p.181-185

2015

Volltextzugriff (PDF)

Understanding patients' attitudes toward communication about the cost of cancer care

Journal of oncology practice, 2012-07, Vol.8 (4), p.e50

2012

Volltextzugriff (PDF)

State of the Art in Imaging and Chemoprevention for High-Risk Patients

Current breast cancer reports, 2013-06, Vol.5 (2), p.125-133

2013

Volltextzugriff (PDF)

Genetic Evaluation for Women at Increased Risk

Managing BRCA Mutation Carriers, 2017, p.15-30

2017

Volltextzugriff (PDF)

Should You Recommend Direct-to-Consumer Genetic Testing for This Patient? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center

Annals of internal medicine, 2020-10, Vol.173 (7), p.563

2020

Volltextzugriff (PDF)

Abstract OT2-24-02: ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-24-02-OT2-24-02

2022

Volltextzugriff (PDF)

Twenty-one-gene recurrence score (RS) in germline (g) CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.10531-10531

2021

Volltextzugriff (PDF)

Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-21

2022

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(23)
Buchkapitel
(1)

Sprache

Englisch
(24)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer

Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test

Patient preferences regarding incidental genomic findings discovered during tumor profiling

Increased epigenetic age in normal breast tissue from luminal breast cancer patients

PALB2 mutations in familial breast and pancreatic cancer

Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update

Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients

Impact of financial burden of cancer on survivors' quality of life

A Case of Pheochromocytoma as a Subsequent Neoplasm in a Survivor of Childhood Embryonal Rhabdomyosarcoma

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer

Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer

Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice

The Number of Lymph Nodes Dissected in Breast Cancer Patients Influences the Accuracy of Prognosis

Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer

The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report

Understanding patients' attitudes toward communication about the cost of cancer care

State of the Art in Imaging and Chemoprevention for High-Risk Patients

Genetic Evaluation for Women at Increased Risk

Should You Recommend Direct-to-Consumer Genetic Testing for This Patient? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center

Abstract OT2-24-02: ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy

Twenty-one-gene recurrence score (RS) in germline (g) CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study

Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer

Suchergebnisse filtern